198 / 658
4
The Utilization of Novel Platform in a LC-MS/MS Work ow for the Analysis of Vitamin D, Testosterone, Immunosuppressants, Chemotherapeutics and Cortisol
very
FIGURE 2. Representative
Tested Using a Prelude SL
ange
oretical)
Intraday Precession Range (%RSD)
High QC Low QC Mid QC High QC
2.11 – 9.72
1.7 – 4.2
1.1 – 2.9
1.4 – 2.7
0.11 – 13.6
7.5 -10.6
1.8 – 2.8
4.7 – 7.6
0.81 – 10.2
5.4 – 8.3
1.7 – 3.5
1.6 – 4.1
0.34 – 8.38
4.8 – 6.0
1.3 – 2.6
1.4 – 2.3
1.63 – 4.84
3.4 – 3.6
1.5 – 2.6
0.8 – 1.2
0.03 – 15.1
4.0 – 6.3
2.3 – 3.9
2.6 – 5.1
0.22 – 5.83
1.1 – 10.9
1.8 – 3.3
1.6 – 4.2
0.26 – 6.98
1.6 – 9.4
1.1 – 3.7
0.9 – 3.4
0.0 – 11.7
1.0 – 1.9
1.1 – 7.4
1.3 – 6.2
0.10 – 10.5
3.3 – 7.5
0.6 – 5.9
2.8 – 7.8
0.3 – 11.2
5.0 – 11.5
2.9 – 6.6
1.9 – 5.1
0.9 – 13.3
6.3 – 6.8
2.3 – 3.9
2.0 – 3.2
y
oretical)
Interday Precession (%RSD)
High QC Low QC Mid QC High QC
3.06
12.2
9.7
12.2
3.75
7.8
8.1
1.8
2.98
9.7
5.4
4.6
3.75
5.1
3.2
2.9
3.12
3.5
1.3
0.15
3.50
3.3
3.8
2.7
3.85
5.6
5.4
3.9
1.28
4.2
4.4
3.1
3.74
4.0
2.0
5.9
0.48
5.5
2.8
7.5
2.87
3.9
4.0
4.8
0.00
3.4
3.1
3.9
FIGURE 1. Standard Curves for Each Compound Tested Using a Prelude SLPC
TM
LC/MS/MS System
Linearity (r
2
)
Recovery
0.992 – 0.998
87.3 – 93.9
0.998 – 0.999
86.9 – 93.9
0.992 – 0.998
88.5 – 95.2
0.998 – 0.999
87.3 – 97.9
0.994 – 0.999
99.9 – 103.5
0.997 – 0.999
88.3 – 114.1
0.995 – 0.998
89.4 – 93.5
0.993 – 0.999
96.6 – 102.1
0.991 – 0.998
92.0 – 110.2
0.992 – 0.998
102 – 111.8
0.992 – 0.998
92.2 – 94.5
0.992 – 0.996
95.0 - 98.9
0.5
1.0
1.5
2.0
0
5000
10000
15000
20000
Busulf
Time (min)
Intensity (mv)
0.5
1.0
1.5
2.0
0
2000
4000
6000
8000
10000
12000
14000
Time (min)
Intensity (mv)
0.5
1.0
1.5
2.0
0
200
400
600
800
25-Hy
Time (min)
Intensity (mv)
0.5
1.0
1.5
2.0
0
100
200
300
400
500
600
Tes
Time (min)
Intensity (mv)
0.5
1.0
1.5
2.0
0
500
1000
1500
2000
Time (min)
Intensity (mv)
0.5
1.0
1.5
2.0
0
500
1000
1500
2000
2500
3000
Time (min)
Intensity (mv)
0
200 400 600 800 1000 1200 1400 1600 1800 2000
0
10
20
30
40
50
Cyclosporin A
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
10
20
30
40
50
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Sirolimus
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
10
20
30
40
50
0.0
0.5
1.0
1.5
2.0
2.5
Everolimus
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
10
20
30
40
50
0
1
2
3
4
Tacrolimus
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
2000
4000
6000
8000
10000
0
10
20
30
40
50
60
70
80
Testosterone
Concentration (pg/mL)
Peak Area Ratio (Sample/IS)
0
50
100
150
200
250
300
350
400
0
5
10
15
20
25
Cortisol
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
500
1000
1500
2000
0
5
10
15
20
25
30
Busulfan
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
500
1000
1500
2000
0
10
20
30
40
50
60
70
Imatinib
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
100
200
300
400
500
600
700
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Methotrexate
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
20
40
60
80
100
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
25-Hydroxy Vitamin D2
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
20
40
60
80
100
0
1
2
3
4
5
6
25-Hydroxy Vitamin D3
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)
0
200
400
600
800
1000
0
1
2
3
4
Docetaxel
Concentration (ng/mL)
Peak Area Ratio (Sample/IS)